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The pathogenesis of juvenile idiopathic arthritis (JIA) is not fully understood. So, this
study was conducted to investigate the clinical usefulness of serum IL-33 levels as an
indicator of the disease activity in JIA. Methods. This cross-sectional study was
conducted on 45 JIA patients. All patients were subjected to detailed history taking,
complete clinical examination with emphasis on pattern and distribution of articular and
extra-articular involvement. Disease activity score (DAS28) was assessed. Venous blood
(10 ml) was collected to assess routine laboratory investigations in addition to IL-33.
Results . Most of patients had sudden arthritis onset (64.4%) and (95.6%) had
progressive course. 6 patients (13.3%) of patients had oligoarticular arthritis, 17 patients
(37.8%) had polyarticular arthritis and 22 patients (48.9%) had systemic arthritis. 88.9%
had emotional aggravation factor, while 86.7% had medication and movement as
relieving factors. Only 8.9% of patients’ diseases are controlled, 46.7% had relapse, and
6.7% stopped treatment. 66.7% of patients had good response and 33.3% had poor
response. JIA patients had a significantly higher serum IL-33 levels compared to IL-33
serum in the control group (p=0.008). There was significant positive correlation between
IL-33 with duration of disease (p=0.002, r=0.612), DAS28CRP (p<0.001, r=0.705) and
DAS28_ESR (p=0.001, r=0.667), However, serum IL- 33 levels did not significantly
correlate with the levels of serum CRP or ESR. Conclusions. JIA patients have
significantly elevated IL-33 serum concentrations and that considerably correlated with
clinical, laboratory and activity parameters of disease suggesting that it could be a
valuable marker of JIA disease activity.
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INTRODUCTION
Juvenile idiopathic arthritis (JIA) is a

patients and IL-33 was released from fibroblast-

heterogeneous and multifactorial inflammatory

like synoviocytes after stimulation with TNF-a

disease

joint

and IL-1b [5]. Furthermore, IL-33 levels in sera

inflammation in children with onset ages

and synovial fluids correlated with disease

younger than 16 years. It is the most common

activity [6].

characterized

by

chronic

chronic rheumatic disease of childhood and an

In JIA patients, previous report found

important cause of disability in them. JIA has

that serum IL-33 was elevated in patients with s-

different subtypes that are defined based on the

JIA [7, 8]. So, this study was conducted to

number of joints involved in the first 6 months

investigate clinical usefulness of serum IL-33

of disease and the extra-articular involvement

levels as an indicator of disease activity in other

[1].

subtypes
The pathogenesis of JIA is not fully

of

JIA

and

determined

their correlation with measures of disease

understood but high numbers of autoreactive T

activity.

cells are observed in inflamed joints in patients

Methods

with poly-JIA, indicating an antigen-driven

This

cross-sectional

study

was

activation of the adaptive immune system might

conducted on 45 JIA patients fulfilling the

play a role in the pathogenesis of poly-JIA [2].

International

League

of

Associations

for

Interleukin-33 (IL-33) is a novel IL-1

Rheumatology (ILAR) classification criteria for

family cytokine that plays a major role in

JIA from the Rheumatology and Immunology

inflammatory,

autoimmune

Departments, inpatient and outpatient clinics,

diseases. IL-33 is a nuclear protein that is

Mansours University Hospital from May to

constitutively

December 2018.

infectious,

expressed

and

in

epithelial

and

endothelial cells, fibroblast, and activated

Patients were excluded if they age >15 years,

macrophage [3].

had a recent infection, malignancy, other

There is increasing evidence in both
humans

and

mouse

models

autoimmune disease, DM, IBD or received antiTNF in the past 3 months.

that IL-33 plays a role in the development and

All JIA patients were subjected to

progression of rheumatoid arthritis (RA). In

detailed history taking, full clinical examination

human RA, IL-33 expression in fibroblast-like

with emphasis on pattern and distribution of

synoviocytes increases after stimulation by

articular involvement, presence of uveitis and

TNF-a with or without IL-1b [4].

other

Previous studies revealed that IL-33 is

extraarticular

findings

and

current

medications.

elevated in sera and synovial fluids from RA
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Juvenile

arthritis

disease

activity

score

coefficient was used to test linear associations

(JADAS28) was assessed in oligoarticular and

between variables.

polyarticular patients as its performance in

Results

systemic-onset is unclear. Disease activity was

The mean age of the 45 patients was

graded to high, moderate and low according to

11.29±3.43 years ranged from 3.5-16 years; 32

Beukelman et al. [9] and inactive disease was

females (71.1%) and 13 males (28.9%) (F: M

identified using Wallace criteria [10].

2.5:1). Nearly half of them have rural residence.

Venous blood (10 ml) was collected and

Most of patients (97.8%) are students, 28

separated into two tubes: one on EDTA for

(62.2%) had moderate socioeconomic status, 11

Complete blood count (CBC) and IL-33 relative

(24.4%)

gene expression and the other left to clot for 10

socioeconomic status. Most of patients had

15 min. Serum was centrifuged (2000 rpm for 10

negative consanguinity. 21 (46.7%) had disease

min.)

clinical

duration from 1 to 5 years, 15 (33.3%) less than

chemistry tests: aminotransferases (AST, ALT),

one year and 9 (20.0%) more than five years of

ferritin,

disease.

and

used

for

C-reactive

protein (CRP), rheumatoid factor (RF) and
serum

IL-33.

low

and

6

(13.3%)

had

high

In this study,6 patients (13.3%) of

Another

patients had oligoarticular arthritis, 17 patients

blood sample on citrate was collected to assay

(37.8%) had polyarticular arthritis and 22

the erythrocyte sedimentation rate (ESR). Serum

patients (48.9%) had systemic arthritis. 24.4% of

IL-33 level was assessed by enzyme-linked

patients had three years delayed diagnosis,

immunosorbent assay (ELISA).

22.2% had two years, 17.8% had one year and

Statistical analysis

20% had six months delayed diagnosis. Most of

The collected data were tabulated and

patients had sudden arthritis onset (64.4%) and

analyzed using SPSS version 16 software.

(95.6%) had progressive course. Most of

Categorical data were presented as number and

patients

percentages

were

distribution. 88.9% had emotional aggravation

expressed as mean and standard deviation. Chi

factor, while 86.7% had medication and

square test (x2), fisher's exact test and analysis

movement as relieving factors. Only 8.9% of

of variance (f) test were used as tests of

patients’ diseases are controlled, 46.7% had

significance. Kruskal-Wallis tests were used for

relapse, and 6.7% stopped treatment. 66.7% of

nonparametric variables. We used Fisher’s exact

patients had good response and 33.3% had poor

test and Chi-square test (X2) to compare

response.

while

quantitative

data

categorical variables. Spearman’s correlation

(64.4%)

Regarding

had

general

treatment,

sites

95.6%

of

take

steroids, 46.7% on methotrexate, 2.2% on
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Tocilizumab with 51.1% of patients with

years and 8.9% with duration of medications

duration of medications less than one year, 40%

more than 5 years.

with duration of medications between 1 to 5
Table 1. Associated manifestations of the study patients.
Manifestation
Morning stiffness
Less 1hour
More than hour
General manifestation
Fever, fatigue
Anorexia, loss appetite
All
Skin mucus membrane
Rash
Normal
Psorasis start first then
progress to arthritis
Ocular symptoms
Itching
Redness
Normal
Uveitis
Present
Absent
Genitourinary manifestation
Discharge
Normal
CVS manifestation
Dyspnea
Normal
CNS manifestation
Headache
Normal
GIT manifestation
Heart burn
Normal

(n=45)
1 (2.2%)
44 (97.8%)
15 (33.3%)
1 (2.2%)
29 (64.4%)
16 (35.6%)
26 (57.8%)
3 (6.7%)

19 (42.2%)
7 (15.6%)
19 (42.2%)
3 (6.7%)
42 (93.3%)
1 (2.2%)
44 (97.8%)
1 (2.2%)
44 (97.8%)
1 (2.2%)
44 (97.8%)
27 (60.0%)
18 (40.0%)

Table 1 shows that 97.8% had morning stiffness more than one hour, 33.3% had fever and fatigue, 35.6%
had skin rash, 42.2% had eye itching, 6.7% had uveitis, 2.2% had genitourinary discharge, 2.2% had
dyspnea and 60% had heart burn.
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Table 2. Radiological assessment of the study patients.
(n=45)
X-ray
2 (4.4%)
2 (4.4%)
3 (6.7%)
1 (2.2%)
37 (82.2%)

Wrist, erosion
Wrist, elbow erosion
Wrist, elbow sclerosis
Knee erosion
Normal
MRI
Fat infiltration
Bone erosion, edema, fat infiltration
Normal
Regarding radiological evaluation, 4.4% of patients had wrist and elbow

1 (2.2%)
2 (4.4%)
42 (93.3%)
erosion, 6.7% had wrist and

elbow sclerosis, 2.2% had knee erosion by x-ray. 2.2% of patients had fat infiltration and 4.4% had bone
erosion and edema by MRI as shown in table 2
Table 3. Laboratory results among the study patients.
Urine analysis (Normal)
RF (negative)
ACCP (negative)
HLAB27

Positive

Negative
ANA (negative)
DAS28_CRP

Moderate activity (3.2 to 5.1)

High activity (>5.1)
DAS28_ESR

Moderate activity

High activity
WBCs(103/ul3)
HB(g/dL)
Platelet(103/ul3)
Creatinine(mg/dl)
ALT(Iu/l)
AST(Iu/l)
Albumin(g)
Bilirubin(mg/dl)
Ferritin(mg/dl)
CRP(mg/dl)
ESR(mm/1sth)
IL33(ng/l)

Published by Mansoura Medical Journal, 2023

(n=45)
45 (100%)
45 (100%)
45 (100%)
2 (4.4%)
43 (95.6%)
45 (100%)
6 (13.3%)
39 (86.7%)
4 (8.9%)
41 (91.1%)
7.98±3.26
10.39±1.44
284 (133-3257)
0.76±0.13
30 (16-85)
25 (17-80)
3.98±0.53
0.678±0.15
50 (15-2000)
30 (5-100)
25 (10-80)
11.5 (4.3-40.8)
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RF; rheumatoid factor, ACCP; anti-Cyclic Citrullinated Peptide, ANA; antinuclear antibody, WBCs;
white blood cells, HB; hemoglobin, ALT; Alanine aminotransferase, AST; aspartate aminotransferase,
CRP; C reactive protein, ESR; erythrocyte sedimentation rate, IL; interleukin.
As shown in table 3, all patients had normal urine analysis, negative RF, ACCP and ANA. 86.7% had
high disease activity by DAS28CRP and 91.1% had high disease activity by DASESR. Patients had
median IL-33 level of 6.5 ng/l, ranged from 2.3-40.8.
Table 4. Serum IL-33 among patients regarding mode of distribution.
Oligoarticular

Polyarticular (n=17)

(n=6)

Systemic

Control

(n=22)

group

P value

(n=45)
IL33(ng/l)

7.6(4.3-40.8)

32.4(23.5-40.8)

13.8 (8.5-21.5)

1.8(0.7-2.5)

0.008*

Kruskal wallis test used.
*Statistically significant as p<0.05.
As illustrated in table 4, JIA patients had a significantly higher serum IL-33 levels compared to IL-33
serum in the control group (p=0.008).
Table 5. Correlation between serum IL-33 level and disease criteria.
IL-33
P value

r

Duration of disease

0.002*

0.612

CRP

0.109

0.218

ESR

0.223

0.110

DAS28CRP

<0.001*

0.705

DAS28ESR

0.001*

0.667

Pearson correlation test used.
*Statistically significant as p<0.05.
As shown in table 5, there are significant positive correlation between IL-33 with duration of
disease (p=0.002, r=0.612), DAS28CRP (p<0.001, r=0.705) and DAS28ESR (p=0.001, r=0.667),
However, serum IL-33 levels did not significantly correlate with the levels of serum CRP or ESR.

Discussion

minimum of six weeks duration. Although, the

Juvenile idiopathic arthritis (JIA) refers

exact etiology of JIA is still not fully clear,

to a series of unexplained etiology inflammatory

recent advances in molecular biology in the last

arthritis that occur before 16 years and with a
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decade led to better understanding of the disease

and systemic onset. This is in agreement with

[11].

another recent study [15].
Current

insight

the

This is in the same line with Matsuyama et al.

immunopathogenesis of JIA in Egyptian patients

suggested that increased IL-33 levels represent

emphasis a key role of cytokines and other

an enhanced inflammatory process at the joint

immune mediators such as tumor necrosis

level rather than systemic inflammation [16].

factor-alpha

(IL)-1,

Similarly, Ishikawa et al. reported higher serum

markers of apoptosis and gene polymorphism as

IL-33 in seropositive polyarticular subtype than

well as in other studies implicating IL- 6,

JIA patients with systemic-onset. IL-33 serum

chemokines, calgranulins and toll-like receptors

level was higher in seropositive polyarticular

in the initiation and propagation of inflammatory

JIA

process and many of them have been considered

concentrations in seronegative polyarticular and

as possible therapeutic targets [12].

oligoarticular JIA patients [15].

(TNF-a),

into

interleukin

patients

Interleukin-33 has many regulatory

compared

to

its

serum

SF IL-33 was significantly higher than

functions in both physiological and pathological

in

conditions as it is involved in the maintenance of

significantly correlated. This can be attributed to

tissue homeostasis besides its role in the

local IL-33 synthesis in the synovium reported

immune reaction against various infectious and

by others [15].

inflammatory diseases [13].

Carriere et al. considered inflamed synovium as

It is released following tissue injury and act as

a main source of IL-33 as they reported

‘‘alarmin” to activate many immune cells that

increased expression of IL-33 in endothelial

express ST2 receptor such as T helper 2 (Th2)

cells and synovial tissues [6].

cells, regulatory T cells (Tregs), mast cells,

Furthermore, Palmer et al. described increased

eosinophils and macrophages [14].

IL-33

So, this study aimed to investigate
clinical usefulness of serum IL-33 levels as an
indicator of disease activity in other subtypes of

the

serum

concentrations

expression

by

and

cultured

both

synovial

fibroblasts following stimulation with TNF-a
[17].
In

the

present

study,

there

were

JIA and determined their correlation with

significant positive correlation between IL-33

measures of disease activity.

with duration of disease (p=0.002, r=0.612),

In this study, IL-33 serum levels were

DAS28CRP (p<0.001, r=0.705) and DAS28ESR

significantly higher than their levels in controls.

(p=0.001, r=0.667), However, serum IL-33

IL-33 serum levels were significantly higher in

levels did not significantly correlate with the

polyarticular patients compared to oligoarticular

levels of serum CRP or ESR.
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In agreement with another study, IL-33

level in the SF. Also, the relation between IL-33

serum and SF levels had a significant positive

and JIA disease activity was evaluated using

correlation

MSUS in addition to the clinical and laboratory

with

different

disease

activity

parameters such as tender and swollen joint
counts, ESR, CRP, JADAS27 as well as
ultrasonographic synovitis activity score [15].
Binding of IL-33 to ST2 receptor leads to
activation of many intracellular pathways that
enhance

inflammation

through

many

mechanisms as degranulation of mast cells, the

parameter.
A limitation of this work lies in the
relative low number JIA patients and the crosssectional study design. Many of the patients
were on medications thus the exact effect of
medications on IL-33 was not assessed.
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